Loading organizations...
§ Private Profile · Qixia, Shandong, China
Biotechnology company developing analgesics for chronic and acute pain management, focused on drug solubility.
Delova Biotech is a biotechnology company based in Nanjing, China, that develops clinical analgesics for the management of chronic and acute pain conditions. Operating from its headquarters in the Xuanwu District, the organization utilizes proprietary platforms, specifically its SimSol technology, to increase the solubility of various targeted pain relief medications. By enhancing this drug solubility, the enterprise aims to produce therapeutics designed to improve efficacy and safety profiles when compared to traditional analgesic treatments currently available in the broader medical market. Functioning through a standard venture capital business model, the firm has advanced to the Series B-II stage and secured a total of $22.97 million in equity funding to support its ongoing clinical drug development pipeline. Delova Biotech was officially established in 2017 to address specific unmet medical needs within the global pharmaceutical and biotechnology sectors.
Delova Biotech has raised $21.1M across 2 funding rounds.
Delova Biotech has raised $21.1M in total across 2 funding rounds.
Delova Biotech has raised $21.1M across 2 funding rounds. Most recently, it raised $13.8M Series B in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 2, 2024 | $13.8M Series B | — | — | Announced |
| Sep 14, 2020 | $7.3M Seed Plus | Junlian Capital | — | Announced |
Delova Biotech has raised $21.1M in total across 2 funding rounds.
Delova Biotech's investors include Junlian Capital.